Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models
Abstract Allergic rhinitis (AR) is caused by type I hypersensitivity reaction in the nasal tissues. The interaction between CD300f and its ligand ceramide suppresses immunoglobulin E (IgE)-mediated mast cell activation. However, whether CD300f inhibits the development of allergic rhinitis (AR) remai...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-58923-w |
| _version_ | 1827284298210738176 |
|---|---|
| author | Takuma Ide Kumi Izawa Wahyu Diono Anna Kamei Tomoaki Ando Ayako Kaitani Akie Maehara Akihisa Yoshikawa Risa Yamamoto Shino Uchida Hexing Wang Mayuki Kojima Keiko Maeda Nobuhiro Nakano Masahiro Nakamura Toshiaki Shimizu Hideoki Ogawa Ko Okumura Fumihiko Matsumoto Katsuhisa Ikeda Motonobu Goto Jiro Kitaura |
| author_facet | Takuma Ide Kumi Izawa Wahyu Diono Anna Kamei Tomoaki Ando Ayako Kaitani Akie Maehara Akihisa Yoshikawa Risa Yamamoto Shino Uchida Hexing Wang Mayuki Kojima Keiko Maeda Nobuhiro Nakano Masahiro Nakamura Toshiaki Shimizu Hideoki Ogawa Ko Okumura Fumihiko Matsumoto Katsuhisa Ikeda Motonobu Goto Jiro Kitaura |
| author_sort | Takuma Ide |
| collection | DOAJ |
| description | Abstract Allergic rhinitis (AR) is caused by type I hypersensitivity reaction in the nasal tissues. The interaction between CD300f and its ligand ceramide suppresses immunoglobulin E (IgE)-mediated mast cell activation. However, whether CD300f inhibits the development of allergic rhinitis (AR) remains elusive. We aimed to investigate the roles of CD300f in the development of AR and the effectiveness of intranasal administration of ceramide liposomes on AR in murine models. We used ragweed pollen-induced AR models in mice. Notably, CD300f deficiency did not significantly influence the ragweed-specific IgE production, but increased the frequency of mast cell-dependent sneezing as well as the numbers of degranulated mast cells and eosinophils in the nasal tissues in our models. Similar results were also obtained for MCPT5-exprssing mast cell-specific loss of CD300f. Importantly, intranasal administration of ceramide liposomes reduced the frequency of sneezing as well as the numbers of degranulated mast cells and eosinophils in the nasal tissues in AR models. Thus, CD300f–ceramide interaction, predominantly in mast cells, alleviates the symptoms and progression of AR. Therefore, intranasal administration of ceramide liposomes may be a promising therapeutic approach against AR by targeting CD300f. |
| first_indexed | 2024-04-24T09:53:23Z |
| format | Article |
| id | doaj.art-86f2797652e548cc944bc465f4ee2c59 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T09:53:23Z |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-86f2797652e548cc944bc465f4ee2c592024-04-14T11:16:30ZengNature PortfolioScientific Reports2045-23222024-04-0114111510.1038/s41598-024-58923-wIntranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine modelsTakuma Ide0Kumi Izawa1Wahyu Diono2Anna Kamei3Tomoaki Ando4Ayako Kaitani5Akie Maehara6Akihisa Yoshikawa7Risa Yamamoto8Shino Uchida9Hexing Wang10Mayuki Kojima11Keiko Maeda12Nobuhiro Nakano13Masahiro Nakamura14Toshiaki Shimizu15Hideoki Ogawa16Ko Okumura17Fumihiko Matsumoto18Katsuhisa Ikeda19Motonobu Goto20Jiro Kitaura21Atopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineDepartment of Materials Process Engineering, Nagoya UniversityAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineDepartment of Otorhinolaryngology, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineDepartment of Otorhinolaryngology, Juntendo University Graduate School of MedicineDepartment of Otorhinolaryngology, Juntendo University Graduate School of MedicineDepartment of Materials Process Engineering, Nagoya UniversityAtopy (Allergy) Research Center, Juntendo University Graduate School of MedicineAbstract Allergic rhinitis (AR) is caused by type I hypersensitivity reaction in the nasal tissues. The interaction between CD300f and its ligand ceramide suppresses immunoglobulin E (IgE)-mediated mast cell activation. However, whether CD300f inhibits the development of allergic rhinitis (AR) remains elusive. We aimed to investigate the roles of CD300f in the development of AR and the effectiveness of intranasal administration of ceramide liposomes on AR in murine models. We used ragweed pollen-induced AR models in mice. Notably, CD300f deficiency did not significantly influence the ragweed-specific IgE production, but increased the frequency of mast cell-dependent sneezing as well as the numbers of degranulated mast cells and eosinophils in the nasal tissues in our models. Similar results were also obtained for MCPT5-exprssing mast cell-specific loss of CD300f. Importantly, intranasal administration of ceramide liposomes reduced the frequency of sneezing as well as the numbers of degranulated mast cells and eosinophils in the nasal tissues in AR models. Thus, CD300f–ceramide interaction, predominantly in mast cells, alleviates the symptoms and progression of AR. Therefore, intranasal administration of ceramide liposomes may be a promising therapeutic approach against AR by targeting CD300f.https://doi.org/10.1038/s41598-024-58923-w |
| spellingShingle | Takuma Ide Kumi Izawa Wahyu Diono Anna Kamei Tomoaki Ando Ayako Kaitani Akie Maehara Akihisa Yoshikawa Risa Yamamoto Shino Uchida Hexing Wang Mayuki Kojima Keiko Maeda Nobuhiro Nakano Masahiro Nakamura Toshiaki Shimizu Hideoki Ogawa Ko Okumura Fumihiko Matsumoto Katsuhisa Ikeda Motonobu Goto Jiro Kitaura Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models Scientific Reports |
| title | Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models |
| title_full | Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models |
| title_fullStr | Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models |
| title_full_unstemmed | Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models |
| title_short | Intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting CD300f in murine models |
| title_sort | intranasal administration of ceramide liposome suppresses allergic rhinitis by targeting cd300f in murine models |
| url | https://doi.org/10.1038/s41598-024-58923-w |
| work_keys_str_mv | AT takumaide intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT kumiizawa intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT wahyudiono intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT annakamei intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT tomoakiando intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT ayakokaitani intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT akiemaehara intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT akihisayoshikawa intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT risayamamoto intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT shinouchida intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT hexingwang intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT mayukikojima intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT keikomaeda intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT nobuhironakano intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT masahironakamura intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT toshiakishimizu intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT hideokiogawa intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT kookumura intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT fumihikomatsumoto intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT katsuhisaikeda intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT motonobugoto intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels AT jirokitaura intranasaladministrationofceramideliposomesuppressesallergicrhinitisbytargetingcd300finmurinemodels |